+-----------------------+------------+---------+---------------------+
| **Name Kim, Su        |            | **P     |                     |
| Young**               |            | osition |                     |
|                       |            | Title   |                     |
|                       |            | As      |                     |
|                       |            | sistant |                     |
|                       |            | C       |                     |
|                       |            | linical |                     |
|                       |            | Investi |                     |
|                       |            | gator** |                     |
+-----------------------+------------+---------+---------------------+
| **INSTITUTION AND     | **DEGREE** | *       | **FIELD OF STUDY**  |
| LOCATION**            |            | *YEAR** |                     |
+-----------------------+------------+---------+---------------------+
| University of Chicago | B.A. with  | 1990    | English             |
|                       | honor      |         |                     |
| University of Chicago |            | 1996    | Molecular Genetics  |
|                       | M.S.       |         | and Cell Biology    |
| University of Chicago |            | 2000    |                     |
|                       | M.D.       |         | Medicine            |
| University of         |            | 2000    |                     |
| Illinois at Chicago   | Ph.D.      |         | Molecular Genetics  |
+-----------------------+------------+---------+---------------------+

**A. Positions and Honors.**

[Positions]{.underline}

2000-2003 Pediatric Residency Program, University of Texas at Houston

2003-2008 Pediatric Hematology/Oncology Fellowship, National Institutes
of Health and Johns Hopkins University

2008-present Assistant Clinical Investigator, Pediatric Oncology Branch,
National Institutes of Health

[Honors]{.underline}

1990 University of Chicago, President's Award for Student Volunteer
Service, Honorable Mention

1995 University of Chicago, Committee on Cancer Biology, Travel Award

2002 American Association of Pediatric Chairmen, Scientific Symposium
Travel Award

2005 PAS, Pediatric Academic Societies, Travel Grant

2005 NIH, National Institutes of Health, Fellows Award for Research
Excellence

2006 SPR, Society for Pediatric Research, David G. Nathan Award in
Hematology/Oncology

2006 ASCO, American Society of Clinical Oncology, Foundation Merit Award

2007 ASPHO, American Society of Pediatric Hematology/Oncology, Young
Investigator Travel Award

2007 NIH, National Institutes of Health, Fellows Award for Research
Excellence

**B. Publications, Abstracts and Presentations (in chronological
order).**

[Publications]{.underline}

1\. **Kim SY**, McLaggan D, Epstein W. The gdhA gene is located at 38.6
minutes on the Escherichia coli map. J Bacteriol 1990; 172:6127-6128.

> 2\. Stewart MJ, Cox G, Reifel-Miller A, **Kim SY**, Westbrook CA,
> Leibowitz DS. A novel transcriptional suppressor located within a
> downstream intron of the BCR gene. J Biol Chem 1994; 269:10820-10829.

3\. Westbrook CA, Chmura SJ, Arenas RB, **Kim SY**, Otto G. Human APC
gene expression in rodent colonic epithelium in vivo using liposomal
gene delivery. Hum Mol Genet 1994; 3:2005-2010.

4\. Takanishi DM, **Kim SY**, Kelemen PR, Yaremko ML, Kim AH, Ramesar
JE, Horrigan SK, Montag A, Michelassi F, Westbrook CA. Chromosome 8
losses in colorectal carcinoma: localization and correlation with
invasive disease. Mol Diagn 1997; 2:1-8.

5\. **Kim SY**, Horrigan SK, Altenhofen JL, Arbieva ZH, Hoffman R,
Westbrook CA. Modification of bacterial artificial chromosome clones
using cre recombinase: introduction of selectable markers for expression
in eukaryotic cells. Genome Res 1998; 8:404-412.

6\. Arbieva ZH, Banerjee K, **Kim SY**, Edassery SL, Maniatis VS,
Horrigan SK, Westbrook CA. High-resolution physical map and transcript
identification of a prostate cancer deletion interval on 8p22. Genome
Res 2000; 10:244-257.

7\. Zarzour W, Kleta R, Frangoul H, Suwannarat P, Jeong A, **Kim SY**,
Wayne AS, Gunay-Aygun M, White J, Filipovich AH, Gahl WA. Two novel CHS1
(LYST) mutations: clinical correlations in an infant with
Chediak-Higashi syndrome. Mol Genet Metab 2005; 85:125-132.

8\. **Kim SY**, Dabb AA, Glenn DJ, Snyder KM, Chuk MK, Loeb DM.
Intravenous pentamidine is effective as second line Pneumocystis
prophylaxis in pediatric oncology patients. Pediatr Blood Cancer 2007;
in press, available on-line.

9\. **Kim SY**, Tsokos M, Helman LJ. Dilemmas associated with congenital
Ewing sarcoma family tumors. J Pediatr Hematol Oncol 2008; 30:4-7.

10\. **Kim SY**, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, Ren L,
Wong D, Korz W, Salari H, Zhang H, Hwang ST, Khanna C, Helman LJ.
Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development
of murine pulmonary metastases. Clin Exp Metastasis 2008; 25:201-211.

11\. Mussai FJ, Cunningham LC, Rezvani G, Stratakis CA, Reynolds JC,
Nesterova G, Henshaw RM, Levine JE, Helman LJ, Arthur DC, **Kim SY**.
Hypocalcemia in a patient with osteosarcoma and 22q11.2 deletion
syndrome. J Pediatr Hematol Oncol 2008; in press.

[Published Abstracts]{.underline}

1\. **Kim SY**, Arenas RB, Hassell KA, Chmura SJ, Horrigan SK, Westbrook
CA. Evidence for a dominant negative effect of APC in colorectal cancer.
Proc Am Assoc Cancer Res 1995; 36supp:#3450.

2\. **Kim SY**, Arbieva ZH, Berger JS, Wu DT, Banerjee K, Ramesar J,
Horrigan SK, Westbrook CA. High resolution physical mapping of the 8p22
deletion region and a novel strategy utilizing biological assays to
survey for tumor suppressor gene activity. Am J Hum Genet 1996;
59supp:#379.

3\. Arbieva ZH, **Kim SY**, Banerjee K, Berger JS, Spanknebel KA,
Horrigan SK, Westbrook CA. Physical and transcriptional maps of the 8p22
homozygous deletion interval in metastatic prostate carcinoma. Am J Hum
Genet 1997; 61supp:#316.

4\. **Kim SY**, Horrigan SK, Arbieva ZH, Westbrook CA. Modification of
BACs allowing for Neo resistance and GFP selection using Cre-mediated
recombination. Am J Hum Genet 1997; 61supp:#1379.

5\. Arbieva ZH, Banerjee K, **Kim SY**, Kravarusic J, Horrigan SK,
Westbrook CA. Transcript map for the tumor suppressor gene interval of
8p22. Am J Hum Genet 1998; 63supp:#324.

6\. Arbieva ZH, Edassery SL, Banerjee K, **Kim SY**, Horrigan SK,
Westbrook CA. The 8p22 tumor suppressor gene site: identification of
novel expressed sequences. Am J Hum Genet 1999; 65supp:#620.

7\. **Kim SY**, Mendoza A, Midura BV, Khanna C, Wong D, Salari H, Helman
LJ. Inhibition of murine osteosarcoma lung metastases using the CXCR4
antagonist, CTCE-9908. Proc Am Assoc Cancer Res 2005; 46supp:#256.

8\. **Kim SY**, Midura BV, Mendoza A, Wong D, Salari H, Khanna C, Helman
LJ. Inhibition of the CXCL12/CXCR4 chemokine pathway decreases murine
osteosarcoma lung metastases. Pediatr Blood Cancer 2005; 44supp:#407.

9\. **Kim SY**, Midura BV, Mendoza A, Khanna C, Korz W, Wong D, Salari
H, Helman LJ. In vitro and in vivo effects of CXCR4 inhibition in
osteosarcoma. Proc Am Assoc Cancer Res 2006; 47supp:#285.

10\. **Kim SY**, Midura BV, Wong D, Salari H, Khanna C, Mendoza A,
Helman LJ. CXCR4 inhibition leads to decreased adhesion and fewer
metastases in osteosarcoma. Pediatr Blood Cancer 2006; 46supp:#3150.6.

11\. Chuk MK, Dabb AA, **Kim SY**, Glenn DJ, Loeb DM. The use of IV
pentamidine as second line prophylaxis for pneumocystis pneumonia. J
Clin Oncol 2006; 24supp:#9043.

12\. **Kim SY**, Cohen SA, Epps J, Smedley J, Mendoza A, Khanna C, Jones
B, Aziz N, Helman LJ. Reduction of murine osteosarcoma lung metastases
using the dipeptidyl peptidase inhibitor, talabostat. J Clin Oncol 2006;
24supp:#9009.

13\. **Kim SY**, Guimond M, Meany HJ, Strahan S, Cook L, Cohen SA,
Khanna C, Jones B, Aziz N, Helman LJ. Dipeptidyl peptidase inhibition
decreases osteosarcoma tumor formation by targeting stromal elements and
immune stimulation. J Immunother 2006; 29:681.

14\. **Kim SY**, Li WJ, Wincovitch SM, Darko IA, Hong SH, Khanna C, Tuan
RS, Garfield SH, Helman LJ. Modeling the tumor microenvironment in vitro
using a bio-mimetic nanofiber scaffold. Proc Am Assoc Cancer Res 2007;
48supp:#2456.

15\. **Kim SY**, Garfield SH, Wincovitch SM, Hong SH, Darko IA, Li WJ,
Tuan RS, Khanna C, Helman LJ. A 3-dimensional bio-mimetic model of
metastases. Pediatr Blood Cancer 2007; 48supp:#5866.8.

16\. **Kim SY**, Walsh MP, Guimond M, Fry TJ, Mackall CL, Briggs J,
Khanna C, O'Mard DL, Jones B, Aziz N, Helman LJ. In vivo suppression of
metastatic murine osteosarcoma. Pediatr Blood Cancer 2007;
48supp:#5292.1.

17\. **Kim SY**, Lum N, Briggs J, Currier D, Khanna C, Munroe D, Helman
LJ. Identification of stromal genes resulting in osteosarcoma tumor
metastasis. Proc Am Assoc Cancer Res 2008; 49supp:#341.

[Platform Presentations and Associated Awards]{.underline}

1\. **Kim SY**, Arenas RB, Wu DT, Hassell KA, Horrigan SK, Westbrook CA.
Truncated APC proteins alter the adherence of the HCT116 colon cancer
cell line, supporting a dominant negative effect. Cancer Genetics and
Tumor Suppressor Genes Conference. 1995 Frederick MD.

2\. **Kim SY**, Midura BV, Wong D, Salari H, Khanna C, Mendoza A, Helman
LJ. CXCR4 inhibition leads to decreased adhesion and fewer metastases in
osteosarcoma. Pediatric Academic Societies Annual Meeting. 2006 San
Francisco CA. Awarded the David G. Nathan Award in Hematology/Oncology
by SPR.

3\. **Kim SY**, Cohen SA, Epps J, Smedley J, Mendoza A, Khanna C, Jones
B, Aziz N, Helman LJ. Reduction of murine osteosarcoma lung metastases
using the dipeptidyl peptidase inhibitor, talabostat. American Society
of Clinical Oncology Annual Meeting. 2006 Atlanta GA. Awarded the
Foundation Merit Award by ASCO.

4\. **Kim SY**, Li WJ, Wincovitch SM, Darko IA, Hong SH, Khanna C, Tuan
RS, Garfield SH, Helman LJ. Modeling the tumor microenvironment in vitro
using a bio-mimetic nanofiber scaffold. American Association for Cancer
Research Annual Meeting. 2007 Los Angeles CA.

5\. **Kim SY**, Walsh MP, Guimond M, Fry TJ, Mackall CL, Briggs J,
Khanna C, O'Mard DL, Jones B, Aziz N, Helman LJ. In vivo suppression of
metastatic murine osteosarcoma. American Society of Pediatric
Hematology/Oncology Annual Meeting. 2007 Toronto Canada. Awarded the
Young Investigator Travel Award by ASPHO.

**C. Research Support.**

Children's Cancer Foundation, 2007 Research Grant 9/07 -- 8/08

"Defining the Anti-Metastatic Mechanism of FAP Inhibition in
Osteosarcoma"

The goal of this project is to determine whether the metastatic
potential of osteosarcoma cells is augmented by induction of FAP in
stromal cells

Role : PI. Amount : 70,000.

Sarcoma Foundation of America, 2007 Research Grant 7/07 - 6/08

\"Inspecting the Stroma to Eliminate Metastatic Osteosarcoma\"

The goal of this project is to identify the molecular signals that occur
between osteosarcoma cells and the surrounding stromal cells that lead
to metastasis using novel in vivo and in vitro techniques

Role : PI. Amount : 25,000. Grant sponsored by Lee Helman (National
Institutes of Health)

> National Cancer Institute, 2007 Director's Intramural Innovation
> Award, Career Development Award 1/07 - 12/07

\"Targeting the Stroma to Improve Outcome in Osteosarcoma\"

The goal of this project is to utilize a 3-dimensional bio-mimetic
tissue culture system to test the hypothesis that metastatic disease
results secondary to a survival advantage when pre-metastatic
osteosarcoma cells interact with stromal cells

Role : PI. Amount : 10,000. Grant sponsored by Lee Helman (National
Institutes of Health)

> National Cancer Institute, 2006 Director's Intramural Innovation
> Award, Career Development Award 1/06 - 12/06

\"CXCR4 Determines Dormancy and the Metastatic Phenotype in Osteosarcoma
Cells\"

The goal of this project is to determine if osteosarcoma cells are
targeted to the bone marrow by utilizing the chemokine receptor CXCR4,
and if so, to explore the possibility that they use the bone marrow as a
sanctuary, where they remain dormant

Role : PI. Amount : 10,000. Grant sponsored by Lee Helman (National
Institutes of Health)

American Academy of Pediatrics, Resident Research Grant 4/02 - 6/02

\"BAC Transfections: A Functional Approach Towards Identification of
Candidate Tumor Suppressor Genes\"

The goal of this project is to determine if BAC clones containing
candidate tumor suppressor genes can be utilized to suppress the growth
of cancer cell lines

Role : PI. Amount : 1,000. Grant sponsored by Anne Killary (MD Anderson
Cancer Center)

**D. Protocols.**

1.  **Kim SY. Protocol Chairperson**. A randomized, double-blinded,
    placebo-controlled, multi-institutional, Phase II.5 study of
    AZD0530, a selective Src kinase inhibitor, in patients with
    recurrent osteosarcoma localized to the lung. In Review.

2.  **Kim SY, NIH Principal Investigator**. A study of bevacizumab, a
    humanized monoclonal antibody against vascular endothelial growth
    factor (VEGF), in combination with chemotherapy for treatment of
    osteosarcoma. In Review.